SS Innovations International (NASDAQ:SSII) Receives Sell (E+) Rating from Weiss Ratings

Key Points

• SS Innovations International's stock has received a "sell (E+)" rating from Weiss Ratings, indicating a negative outlook from analysts.
• As of Wednesday, shares of SS Innovations International traded at $6.72, down by 0.9%, with a one-year range of $2.48 to $22.42.
• Recent institutional investments include new positions by hedge funds such as AlTi Global Inc., Geode Capital Management LLC, and Forum Financial Management LP during the second quarter.

SS Innovations International (NASDAQ:SSII - Get Free Report)'s stock had its "sell (e+)" rating reissued by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

SS Innovations International Stock Down 0.9%

Shares of NASDAQ SSII opened at $6.72 on Wednesday. The firm's 50-day simple moving average is $6.48. SS Innovations International has a 1 year low of $2.48 and a 1 year high of $22.42.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SSII. AlTi Global Inc. acquired a new position in shares of SS Innovations International during the second quarter valued at about $121,000. Geode Capital Management LLC purchased a new position in SS Innovations International during the second quarter worth about $122,000. Finally, Forum Financial Management LP purchased a new position in SS Innovations International during the second quarter worth about $344,000.

About SS Innovations International

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.